NCT00998192 - A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2013

Study Completion Date

August 31, 2015

Conditions

Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

Interventions

BIOLOGICAL

REOLYSIN

3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle

DRUG

Paclitaxel

200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle

DRUG

Carboplatin

6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle

Trial Locations (17)

10504

Advanced Oncology Associates, Armonk

18704

Medical Oncology Associates of Wyoming Valley, Kingston

24501

Lynchburg Hematology Oncology Clinic, Lynchburg

34471

Ocala Oncology Center, Ocala

45042

Signal Point Clinical Research Center, LLC, Middletown

46260

Investigative Clinical Research of Indiana, LLC, Indianapolis

60714

Illinois Cancer Specialists, Niles

75042

Texas Oncology - Garland, Garland

75067

Texas Oncology - Lewisville, Lewisville

75702

Texas Oncology - Tyler, Tyler

76014

Texas Oncology - Arlington South, Arlington

76022

Texas Oncology - Bedford, Bedford

76104

Texas Oncology - Fort Worth, Fort Worth

76210

Texas Oncology - Denton South, Denton

78229

Cancer Therapy & Research Center at UTHSCSA, San Antonio

90048

Cedars-Sinai Medical Center, Los Angeles

78258-3912

Cancer Care Centers of South Texas, San Antonio